Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma_ Comparison of IHC, FISH and Real-Time RT-PCR
Ling Shan, Fang Lian, Lei Guo, et al.

To compare fluorescence in situ hybridization (FISH), immunohistochemistry (IHC) and quantitative real-time reverse
transcription-PCR (qRT-PCR) assays for detection of ROS1 fusion in a large number of ROS1-positive lung adenocatcinoma
(ADC) patients.

PLOS ONE, DOI:10.1371/journal.pone.0120422, March 5, 2015

Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients
Qing Zhang, Lei Zhu and Jie Zhang

Although new individual treatments continue to reshape the landscape of clinical care in patientswith lung cancer, most of
the progress has been mainly of benefit to patients with lung adenocarcinomas rather than squamous cell lung carcinoma
(SQCLC). Our study aimed to determine whether the epidermal growth factor receptor (EGFR) gene mutation is present in
pure SQCLC. We further determined the mutation frequency and the clinical and pathological features of groups that are in
high risk for EGFR mutation.

BMC Cancer (2015) 15:88; DOI 10.1186/s12885-015-1056-9

KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients
Ju-Xiang Ye, Yan Liu, Yun Qin, et al.

To investigate gene mutations and DNA mismatch repair (MMR) protein abnormality in Chinese colorectal carcinoma  (CRC)   patients  and  their  correlations  with clinicopathologic features.

World J Gastroenterol, 2015 February 7; 21(5): 1595-1605

Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma
Junliang Lu, Jie Gao, Jing Zhang, et al.

BRAF V600E is the most frequent genetic alteration in papillary thyroid  carcinoma  (PTC); there are ongoing conflicts on its
association with regional lymph node metastasis. And we aimed to test this as-sociation in a referred sample in a single
institute in China.

Int J Clin Exp Pathol, 2015;8(1):793-799


探討中國非小細胞肺癌( NSCLC) 患者中K-Ras和表皮生長因子受體( EGFR) 基因突變情況及其與臨床病理特征的關系。

臨床腫瘤學雜志 2014年9月第19卷第9期 (Chinese Clinical Oncology, Sep. 2014, Vol.19, No.9)

Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies
Yan-Gang Qu, Qian Zhang, Qi Pan, et al.

Epidermal growth factor receptor (EGFR) mutation status plays an important role in therapeutic decision making for non-small cell lung cancer (NSCLC) patients. Since EGFR mutation-specific antibodies (E746-A750del and L858R) have been developed,
EGFR mutation detection by immunohistochemistry (IHC) is a suitable screening test. On this basis, we want to establish a new screening test, quantum dots immunofluorescence histochemistry (QDs-IHC), to assess EGFR gene mutation in NSCLC tissues, and we compared it to traditional IHC and amplification refractory mutation system (ARMS). 

International Journal of Nanomedicine, 2014:9 5771-5778